Pulmonx Corp Stock EBITDA
| LUNG Stock | USD 1.61 0.23 12.50% |
Fundamental analysis of Pulmonx Corp allows traders to better anticipate movements in Pulmonx Corp's stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| EBITDA | -50.8 M | -53.3 M |
Pulmonx | EBITDA | Build AI portfolio with Pulmonx Stock |
Pulmonx Corp Company EBITDA Analysis
Pulmonx Corp's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Pulmonx Corp EBITDA | (50.79 M) |
Most of Pulmonx Corp's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pulmonx Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pulmonx EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Pulmonx Corp is extremely important. It helps to project a fair market value of Pulmonx Stock properly, considering its historical fundamentals such as EBITDA. Since Pulmonx Corp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pulmonx Corp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pulmonx Corp's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Pulmonx Ebitda
Ebitda |
|
According to the company disclosure, Pulmonx Corp reported earnings before interest,tax, depreciation and amortization of (50.79 Million). This is 105.79% lower than that of the Health Care Equipment & Supplies sector and 107.91% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.3% higher than that of the company.
Pulmonx EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmonx Corp's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmonx Corp could also be used in its relative valuation, which is a method of valuing Pulmonx Corp by comparing valuation metrics of similar companies.Pulmonx Corp is currently under evaluation in ebitda category among its peers.
Pulmonx Corp Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pulmonx Corp from analyzing Pulmonx Corp's financial statements. These drivers represent accounts that assess Pulmonx Corp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pulmonx Corp's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 2.5B | 1.2B | 312.7M | 484.2M | 556.8M | 529.0M | |
| Enterprise Value | 2.3B | 1.0B | 235.4M | 442.1M | 508.4M | 482.9M |
Pulmonx Corp Institutional Holders
Institutional Holdings refers to the ownership stake in Pulmonx Corp that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pulmonx Corp's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pulmonx Corp's value.| Shares | Braidwell Lp | 2025-03-31 | 752.5 K | Jpmorgan Chase & Co | 2025-03-31 | 654.4 K | Parkman Healthcare Partners Llc | 2025-03-31 | 611.9 K | Rock Springs Capital Management Lp | 2025-03-31 | 503.7 K | D. E. Shaw & Co Lp | 2025-03-31 | 486.6 K | Marshall Wace Asset Management Ltd | 2025-03-31 | 459.9 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 397.3 K | Northern Trust Corp | 2025-03-31 | 364.9 K | Franklin Resources Inc | 2025-03-31 | 357.9 K | Fmr Inc | 2025-03-31 | 5.4 M | Primecap Management Company | 2025-03-31 | 5.4 M |
Pulmonx Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 36.81 M | ||||
| Shares Outstanding | 40.26 M | ||||
| Shares Owned By Insiders | 4.40 % | ||||
| Shares Owned By Institutions | 92.12 % | ||||
| Number Of Shares Shorted | 1.44 M | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 0.72 X | ||||
| Revenue | 83.79 M | ||||
| Gross Profit | 66.16 M | ||||
| EBITDA | (50.79 M) | ||||
| Net Income | (56.39 M) | ||||
| Cash And Equivalents | 162.09 M | ||||
| Cash Per Share | 4.35 X | ||||
| Total Debt | 56.47 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 9.43 X | ||||
| Book Value Per Share | 1.71 X | ||||
| Cash Flow From Operations | (31.54 M) | ||||
| Short Ratio | 4.35 X | ||||
| Earnings Per Share | (1.43) X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 6.75 | ||||
| Number Of Employees | 291 | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 64.81 M | ||||
| Total Asset | 162.85 M | ||||
| Retained Earnings | (467.56 M) | ||||
| Working Capital | 111.81 M | ||||
| Net Asset | 162.85 M |
About Pulmonx Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmonx Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmonx Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmonx Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Pulmonx Corp Piotroski F Score and Pulmonx Corp Altman Z Score analysis. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share | Quarterly Revenue Growth 0.148 | Return On Assets | Return On Equity |
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.